Arvinas, Inc. Files 8-K Report
Ticker: ARVN · Form: 8-K · Filed: Oct 20, 2025 · CIK: 1655759
| Field | Detail |
|---|---|
| Company | Arvinas, Inc. (ARVN) |
| Form Type | 8-K |
| Filed Date | Oct 20, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Corporate Reporting
Related Tickers: ARVN
TL;DR
ARVN filed an 8-K, mostly standard stuff, no major news yet.
AI Summary
On October 20, 2025, Arvinas, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates routine corporate reporting by Arvinas, Inc. to the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report with no immediate indication of significant new risks or material adverse events.
Key Players & Entities
- ARVINAS, INC. (company) — Registrant
- October 20, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- New Haven, Connecticut (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The filing is for a Current Report on Form 8-K, reporting on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
What is the exact name of the registrant?
The exact name of the registrant is Arvinas, Inc.
In which state was Arvinas, Inc. incorporated?
Arvinas, Inc. was incorporated in Delaware.
What is the address of Arvinas, Inc.'s principal executive offices?
The address is 5 Science Park, 395 Winchester Ave., New Haven, Connecticut 06511.
What is the telephone number for Arvinas, Inc.?
The telephone number is (203) 535-1456.
Filing Stats: 785 words · 3 min read · ~3 pages · Grade level 13.1 · Accepted 2025-10-20 06:06:41
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share ARVN The Nasdaq Stock Market
Filing Documents
- arvn-20251020.htm (8-K) — 30KB
- esmopressreleasefinal.htm (EX-99.1) — 14KB
- esmopressreleasefinal001.jpg (GRAPHIC) — 283KB
- esmopressreleasefinal002.jpg (GRAPHIC) — 235KB
- esmopressreleasefinal003.jpg (GRAPHIC) — 316KB
- esmopressreleasefinal004.jpg (GRAPHIC) — 167KB
- 0001628280-25-045445.txt ( ) — 1546KB
- arvn-20251020.xsd (EX-101.SCH) — 2KB
- arvn-20251020_lab.xml (EX-101.LAB) — 23KB
- arvn-20251020_pre.xml (EX-101.PRE) — 13KB
- arvn-20251020_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On October 20, 2025, Arvinas, Inc. (the "Company") issued a press release announcing new patient-reported outcomes ("PRO") data from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant. These data were presented in a mini oral session at the 2025 European Society for Medical Oncology Congress ("ESMO 2025"). The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. The information in this Item 7.01, including Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Other Events
Item 8.01 Other Events. On October 20, 2025, the Company issued a press release announcing new PRO data from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant. These data were presented in a mini oral session at ESMO 2025. Vepdegestrant is a novel investigational PROteolysis TArgeting Chimera ("PROTAC") estrogen receptor ("ER") degrader which is being developed with Pfizer Inc. as a potential monotherapy for estrogen receptor 1 ("ESR1") mutated, ER-positive ("ER+)/human epidermal growth factor receptor 2-negative ("HER2-") advanced or metastatic breast cancer previously treated with endocrine-based therapy. In the VERITAC-2 clinical trial, in patients with ESR1-mutated disease, vepdegestrant demonstrated a reduced risk of deterioration compared to fulvestrant which was statistically significant in several PRO domains including overall health status, pain severity, and functioning (including role, cognitive, emotional, and social functioning), and vepdegestrant consistently showed reduced risk of deterioration versus fulvestrant across all PRO domains. These PRO data from the VERITAC-2 clinical trial support the clinical benefit of vepdegestrant in patients with ESR1-mutated, ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy. Also presented at ESMO 2025 were results from the TACTIVE-N Phase 2 clinical trial, which evaluated neoadjuvant vepdegestrant in postmenopausal women with ER+/HER2– localized breast cancer. The results presented at ESMO 2025 showed that neoadjuvant vepdegestrant demonstrated biological and clinical activity in this treatment-nave, predominantly ESR1 wild-type population of postmenopausal women with ER+/HER2- localized breast cancer.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Description of Exhibit 99.1 Press Release, dated October 20 , 2025 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARVINAS, INC. Date: October 20, 2025 By: /s/ Andrew Saik Andrew Saik Chief Financial Officer